Importance

Loading Importance Indicators...

Abstract

An inhibitor for restenosis after percutaneous coronary arterioplasty, which comprises, as an active ingredient, a compound of the following formula (1), (1') or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 and R.sup.2 are independently a hydrogen atom, a halogen atom, a trifluoromethyl group, a nitro group, a C1-C6 alkyl group or a C1-C6 alkoxyl group, and R.sup.1 and R.sup.2 may be linked to form a methylenedioxy group; R.sup.3 is an optionally substituted aryl group, an optionally substituted aromatic heterocyclic group, an optionally substituted 5 to 7-membered cycloalkyl or cycloalkenyl group; R.sup.4 is a hydrogen atom, a hydroxyl group, an -S-glutathione residue, an -S-.alpha.-amino acid residue, or an aralkyl group optionally having substituent(s) in the aryl moiety; R.sup.5 is a hydrogen atom or a C1-C6 alkyl group, and R.sup.4 and R.sup.5 may be linked to form a single bond; Y is an oxygen atom or a sulfur atom; n is an integer of from 0 to 5, and the selenium atom may be oxidized. The inhibitor of the present invention exhibits excellent inhibitory effect against restenosis after PTCA with low toxicity.

Loading the Abstract Image...

First Claim